huTARDBP-Q331K/M337V/A382T Mouse
Product Name
huTARDBP-Q331K/M337V/A382T Mouse
Product ID
C001963
Strain Name
C57BL/6JCya-Tardbptm2(hTARDBP*Q331K*M337V*A382T)/Cya
Backgroud
C57BL/6JCya
Status
When using this mouse strain in a publication, please cite “huTARDBP-Q331K/M337V/A382T Mouse (Catalog C001963) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Gene Alias
ALS10, TDP-43
NCBI ID
Chromosome
Chr 1
MGI ID
Datasheet
Strain Description
TAR DNA-binding protein 43 (TARDBP/TDP43) is a crucial protein involved in RNA processing, transport, and metabolism. Its aggregation in the cytoplasm is a key pathological feature of several neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). TDP43 is a multifunctional nuclear protein and is the main component of ubiquitin-positive cytoplasmic inclusions found in residual motor neurons of sporadic and familial ALS, with cytoplasmic TDP43 inclusions observed in almost all ALS cases [1]. TDP43 is typically localized in the cell nucleus but can shuttle between the nucleus and cytoplasm to perform various functions, including regulating RNA splicing, transport, and homeostasis. Both cytoplasmic mislocalization and nuclear loss of TDP43 are associated with ALS and FTD, and the proper function of TDP43 is ensured by strictly controlled nucleocytoplasmic transport, which regulates its expression levels and correct cellular localization [2].
The synergy of the Q331K, M337V, and A382T mutations within the C-terminal glycine-rich domain of TARDBP creates a potent driver of neurodegeneration by fundamentally altering the protein's biophysical properties and cellular localization [3]. Individually, Q331K promotes the formation of toxic C-terminal fragments and disrupts RNA splicing, while M337V accelerates the kinetics of irreversible fibrillization and impairs mitochondrial transport [4]. A382T further exacerbates this pathology by promoting nucleocytoplasmic mislocalization and inducing R-loop-mediated DNA damage [5]. When combined in a humanized model, these mutations act in concert to trigger robust TDP-43 proteinopathy, characterized by the loss of essential nuclear regulatory functions and the gain of cytoplasmic aggregate toxicity. This pathological cascade directly mirrors the clinical progression of ALS and FTD, leading to selective motor neuron loss, cognitive decline, and the formation of phosphorylated inclusions that are hallmarks of the ALS-FTD spectrum.
huTARDBP-Q331K/M337V/A382T was generated by introducing the p.Q331K (CAG to AAG), p.M337V (ATG to GTG), and p.A382T (GCA to ACA) point mutations into exon 6 of the human TARDBP gene in huTARDBP mice (Catalog Number: C001418). This model serves as a valuable tool for studying neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), and can be used to investigate the effects of TDP‑43 protein aggregation in related disorders.
Reference
Lye YS, Chen YR. TAR DNA-binding protein 43 oligomers in physiology and pathology. IUBMB Life. 2022 Aug;74(8):794-811.
Chen-Plotkin AS, Lee VM, Trojanowski JQ. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010 Apr;6(4):211-20.
Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, Baralle F, de Belleroche J, Mitchell JD, Leigh PN, Al-Chalabi A, Miller CC, Nicholson G, Shaw CE. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008 Mar 21;319(5870):1668-72.
Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009 Jul 24;284(30):20329-39.
Giannini M, Bayona-Feliu A, Sproviero D, Barroso SI, Cereda C, Aguilera A. TDP-43 mutations link Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated DNA damage. PLoS Genet. 2020 Dec 10;16(12):e1009260.
Strain Strategy
Figure 1. Diagram of the gene editing strategy for the generation of huTARDBP mice. The sequences from the ATG start codon to the TAG stop codon of the endogenous mouse Tardbp gene were replaced with the sequences from the ATG start codon to the TAG stop codon of the human TARDBP gene.
Figure 2. Diagram of the gene editing strategy for the generation of huTARDBP-Q331K/M337V/A382T mice. The p.Q331K (CAG to AAG), p.M337V (ATG to GTG), and p.A382T (GCA to ACA) point mutations were introduced into human TARDBP exon 6.
Application Area
Research on Amyotrophic Lateral Sclerosis (ALS);
Research on Frontotemporal Lobar Degeneration (FTLD);
Research on other neuromuscular and neurodegenerative diseases.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.